Check out your Company Bowl for anonymous work chats.
GRAIL announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents’ fees and other expenses.
Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia
GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare company whose mission is to detect cancer early when it can be cured, today announced its spin-off from Illumina (NASDAQ: ILMN) is complete, and GRAIL will be listed and commence regular-way trading on the Nasdaq under the symbol “GRAL” as of June 25, 2024. “With this spin-off, GRAIL is taking another important step in our journey to shift the paradigm in early cancer detection,” said Bob Ragusa, Chief Executive Officer at GRAIL. “There is nothing acceptable about the status quo in cancer screening today. At GRAIL, we have an unprecedented opportunity to establish a new standard of care through Galleri® – our clinically-validated, commercially available multi-cancer early detection test, which screens for many of the deadliest cancers, including those with no recommended screening tests today. As a publicly traded company, we will continue our important work to address one of society’s biggest healthcare challenges, and to establish and maintain a market leading position in cancer detection. We have built a strong foundation and track record of innovation, which we will leverage to deliver value for patients, healthcare providers, healthcare systems, shareholders and our employees.”
We’re honored to be named on Fast Company’s 2022 World Changing Ideas Awards list, which focuses on organizations pursuing innovation for the good of society and the planet. GRAIL, a healthcare company whose mission is to detect cancer early, when it can be cured, received honorable mention for the Galleri® multi-cancer early detection test.
We are pleased to announce GRAIL’s multi-cancer early detection test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration, a significant milestone in our mission to #DetectCancerEarly. Read more about this and other important business updates here http://glassdoor.com/slink.htm?key=vMPh6
Data presented today at #AACR19 (Abstract #3372) help further understanding of the nature of cfDNA by examining tumor- and blood-derived variant cfDNA fragment lengths across ~20 cancer types. Click here to view the poster http://glassdoor.com/slink.htm?key=vMnBf
We’re pleased to announce the appointment of Catherine Friedman as Chair of the GRAIL Board and promotion of Alex Aravanis to Chief Scientific Officer. Learn more in our press release: http://glassdoor.com/slink.htm?key=vQhJq #DetectCancerEarly
We're excited to announce our plans to initiate a new study in early 2019 in partnership with UCLHNHS, ULCH and LCA. The SUMMIT study is designed to enroll 50,000 men and women in the UK, and will evaluate our blood test in development to #DetectCancerEarly. Learn more about this study here: http://glassdoor.com/slink.htm?key=vQh2A
We’re happy to share that we have completed enrollment for our STRIVE study. Learn more about our mission to help #DetectCancerEarly from our VP of Clinical Development, Dr. Anne-Renee Hartman: http://glassdoor.com/slink.htm?key=vQSuZ
We are pleased to announce Renée Galá will be joining GRAIL in January as Chief Financial Officer. Renée has more than 20 years in finance, corporate strategy, and leadership experience, and we look forward to welcoming her to our team. Learn more about her background in our press release: http://glassdoor.com/slink.htm?key=vQrG2 hashtag#DetectCancerEarly
